FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – USA – 04/2025”.
The Monitor is a month-to-month revealed overview of enterprise capital tendencies within the US Healthcare & Life Sciences sector.
As of the top of April 2025 we recognized the next present VC tendencies in the USA:
- Complete Healthcare & Life Sciences funding reached EUR 12,809m (-9% vs. 2024)
- Whereas US VC financing quantity in Healthcare & Life Sciences is declining vs. final 12 months’s quantity, Europe’s financing quantity is 32% increased than final 12 months
- Biotech/Pharma obtained 43% of the full funding quantity (EUR 5,567m) with oncology being the main indication (25%)
- In April Transcarent secured the highest transaction quantity with EUR 437m, adopted by Cognito Therapeutics with EUR 181m and Atsena Therapeutics with EUR 138m
- Illumina (United States) is essentially the most energetic investor (by deal quantity in 2025), adopted by Regeneron Prescribed drugs (United States) and Bain Capital Life Sciences (United States)
To entry the complete report, please click on right here.
By Mathias Klozenbücher und Johannes Hyperlink